Ashwagandha Withanolide Testing: What '5% Standardized' Actually Means and How Labs Detect Adulteration

Two batches arrive labeled identically: ashwagandha root extract, 5% withanolides, HPLC-confirmed. The chromatograms tell a different story. One shows a balanced withanolide profile consistent with root-origin material. The other peaks heavily on withaferin A — the marker compound concentrated in ashwagandha leaf, not root. Both suppliers stand by their COAs. Neither is technically lying.

That’s the problem with ashwagandha testing in 2026. The market is enormous, the label language has converged on a single standard claim, and the analytical complexity underneath that claim is almost never communicated to the brand buying the extract. When we run incoming ashwagandha batches at our lab, we see more variability between same-claiming lots than most of our clients expect.

Here’s what’s actually happening in the lab — and what brands need to understand before they accept a COA at face value.

What “Standardized to 5% Withanolides” Doesn’t Tell You

The phrase sounds precise. It isn’t.

Withanolides aren’t a single compound. They’re a family of more than 40 structurally related steroidal lactones that occur naturally in Withania somnifera, each with distinct biological activity, distribution across plant parts, and stability under different extraction and storage conditions. The most pharmacologically studied include withaferin A, withanolide A, withanolide D, withacoagin, and the withanosides — and the relative proportion of each shifts meaningfully depending on whether the source material is root, leaf, stem bark, or berry.

When a label claims “5% withanolides,” several critical questions go unanswered:

Which withanolides? Some labs sum all detectable withanolide peaks. Others report only the major compounds detectable against their reference standards. A lab using withaferin A as its sole external standard and applying its response factor to all other peaks will produce a different number than a lab running individual certified standards for each major analyte. Both approaches can yield “5%.” Neither result means the same thing.

Measured against what reference material? USP has published an Ashwagandha Root Powdered Extract monograph — a meaningful step toward method harmonization — but adoption across contract labs is still uneven. When we evaluate supplier COAs, one of the first things we look for is which reference standards were used and whether they carry NIST traceability or USP certification. A COA that says “5.3% withanolides by HPLC” with no reference standard documentation is a COA you can’t interrogate.

From which extraction batch? Withanolide concentrations in ashwagandha raw material vary by growing season, geography (Indian versus East African cultivation, for instance), and post-harvest handling. An extract standardized to 5% is actively adjusted — either by blending or by adding concentrated fractions — to hit the target. Knowing how that standardization was achieved matters for lot-to-lot consistency.

The practical result: two products carrying the identical label claim can have radically different phytochemical compositions. For brands building formulas around specific clinical trial data — most commonly the published studies on KSM-66 or Sensoril — this is a serious problem.

Root vs. Leaf: The Plant Part Problem Most Brands Overlook

Under FDA’s dietary supplement cGMP regulations at 21 CFR Part 111, the plant part is part of a component’s identity. Ashwagandha root and ashwagandha leaf are different dietary ingredients with different phytochemical profiles, different historical use data, and different safety records. This isn’t a nuance — it’s a regulatory and scientific distinction that has real product implications.

The root has the longer clinical history. The large majority of published human trials on ashwagandha cognitive and stress-response outcomes used root-derived extracts. KSM-66, one of the best-documented branded extracts, uses root only and targets a minimum of 5% withanolides by its proprietary HPLC method. Sensoril uses both root and leaf, standardizes to a minimum of 10% glycowithanolides, and has its own clinical portfolio — but it’s a different specification, a different phytochemical profile, and a different product.

Adulteration by leaf material in products marketed as root-only is economically motivated and well-documented in the botanical ingredient industry. Leaf is cheaper to source. It also happens to contain higher concentrations of withaferin A, which means it’s easier to hit a “5% withanolides” claim using leaf-adulterated material than with root alone. The problem is that withaferin A at elevated concentrations is cytotoxic — it’s being studied for anti-cancer properties precisely because it disrupts cell cycle function — and its elevated presence in what’s supposed to be a root-origin, adaptogenic extract is a legitimate safety concern, not just a label accuracy issue.

Labs detect root-versus-leaf adulteration through a combination of methods. Withaferin A ratio analysis is the first screen: in an authentic root-only extract, withaferin A is present but not dominant relative to other withanolides. When we see withaferin A comprising a disproportionate fraction of total withanolide content — particularly in an extract claiming a high overall withanolide percentage — that pattern warrants follow-up. Botanical microscopy is the second approach: powdered leaf tissue contains palisade mesophyll and vascular structures that trained analysts can identify in a powdered sample claimed to be root. And DNA barcoding, targeting established markers like ITS2 or trnH-psbA in the chloroplast genome, can confirm Withania somnifera species identity and, in some validated methods, help distinguish plant part origin.

None of these methods is definitive alone. Used together, they paint a picture that a single HPLC number simply cannot.

How Labs Quantify Withanolides — and Where the Numbers Get Slippery

The analytical workhorse for withanolide quantification is reversed-phase HPLC with UV detection, typically running at 227 nm where the withanolide lactone chromophore absorbs. A properly developed and validated method resolves the major withanolides into distinct chromatographic peaks, giving both identity and quantity for each compound.

But method development quality varies enormously across contract labs. And that variance is invisible on a COA unless you know what to look for.

A few technical points that matter in practice:

The selection of mobile phase and gradient conditions affects which compounds are resolved and which co-elute. If withaferin A and another withanolide overlap chromatographically, the summed peak inflates the apparent withaferin A concentration. A lab that hasn’t optimized its method for the specific extract matrix can produce accurate-looking numbers on a poorly resolved chromatogram.

Reference standard calibration is the other pressure point. Single-standard calibration — where one compound’s response factor is applied to all structurally related peaks — introduces systematic error that compounds across analytes. The magnitude of that error depends on how similar the extinction coefficients of the different withanolides are at 227 nm. For a rough total withanolide estimate, single-standard calibration may be acceptable. For a specification-grade result against a contracted potency claim, it isn’t.

High-resolution mass spectrometry (LC-HRMS) and LC-MS/MS add another layer of capability that HPLC-UV alone can’t provide: they allow labs to screen for synthetic adulterants, detect unusual isotope ratios that can indicate spiking with isolated withanolide standards, and confirm compound identities that co-elute or occur at trace levels. If a supplier is enriching an extract with isolated withaferin A to hit a withanolide claim on cheaper base material, targeted LC-MS/MS screening can often catch it.

A credible ashwagandha HPLC test report should include: the column and chromatographic conditions (column brand, dimensions, particle size, gradient program), the reference standards used with lot numbers and expiration dates, individual compound quantification for at least the major withanolides rather than just a summed total, system suitability data showing adequate resolution between key peaks, and the method’s limit of quantitation. A COA that shows only a single number — “5.1% withanolides, HPLC” — gives you no basis for evaluating the reliability of that result.

What to Actually Ask Your Testing Lab For

Most of the ashwagandha COA problems we encounter aren’t deliberate fraud. They’re ambiguity — suppliers providing truthful numbers generated by methods that aren’t comparable to the analytical framework the buyer’s formula was designed around. That gap falls on the brand to close, and 21 CFR Part 111.75 makes it a regulatory obligation: identity testing of incoming components isn’t optional, and for a botanical as variable as ashwagandha, “identity” has to include more than a quick organoleptic check.

A defensible ashwagandha testing program covers three things:

Identity and authenticity: HPLC chromatographic fingerprinting against an authenticated reference extract, DNA barcoding to confirm species, and botanical microscopy on powdered raw materials. If you’re sourcing a branded ingredient like KSM-66 or Sensoril, ask your lab to run the method published by the branded ingredient supplier — or document why your method is equivalent.

Potency with compound-level detail: Full withanolide panel by reversed-phase HPLC with individual quantification, not a summed total. If the extract is standardized to a branded specification, the test should match that specification’s defined analytes.

Purity: Heavy metals per USP <232> limits (lead, cadmium, arsenic, mercury), microbial testing per USP <2021>, and pesticide residue screening calibrated for the country of origin. Indian-cultivated ashwagandha carries pesticide exposure risks specific to South Asian agricultural practices — a generic pesticide screen may not include the compounds most relevant to that origin.

The brands with defensible ashwagandha products five years from now will be the ones who built thorough testing programs before a regulatory inquiry or a consumer complaint created the urgency. Botanical supplements are under increasing FDA scrutiny, and ashwagandha specifically has accumulated enough adverse event reports and identity questions that it’s not a category where minimal testing is a reasonable risk posture.

---

Written by Nour Abochama, Vice President of Operations, Qalitex Laboratories. Learn more about our team

Talk to our team about your testing needs. Contact us

Related from our network

• Supplier qualification and COA verification for botanical raw materials — Ayah Labs covers raw material testing and incoming ingredient qualification for global ingredient sourcing teams.
• FDA audit readiness and 21 CFR Part 111 cGMP compliance consulting — Aurora TIC helps supplement manufacturers prepare documentation and quality systems before FDA inspections.